Onchilles Pharma

Onchilles Pharma is a private, preclinical-stage biotech leveraging its proprietary ELANE pathway platform to develop next-generation, selective cytotoxic therapies. The company's approach targets elevated histone H1, a vulnerability shared across cancer types, aiming to deliver potent tumor killing without damaging immune cells. With a pipeline focused on intratumoral and intravenous biologics for multiple solid tumors, Onchilles is preparing for initial clinical trials in 2025/2026, positioning itself at the intersection of targeted cytotoxicity and immunotherapy.

The ELANE pathway platform exploits elevated histone H1 levels, a hallmark of cancer cells, to trigger selective, immunogenic cancer cell death while sparing healthy tissue and immune cells.

Onchilles operates in the competitive oncology space but claims a unique niche with its selective cytotoxic/immunogenic mechanism. It differentiates from traditional chemotherapy (non-selective) and immunotherapy (indirect action), but may face future competition from other companies developing targeted cytotoxic agents or therapies aiming to induce immunogenic cell death.